---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-21-001149"
form_type: "8-K"
ticker: "USNA"
cik: "0000896264"
company_name: "USANA HEALTH SCIENCES INC"
filed_at: "2021-09-16T23:59:59+00:00"
generated_at: "2026-06-29T03:22:31.085871+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# USANA pre-announces Q3 net sales $265-$270M (down ~10% YoY); cuts FY2021 guidance

## Summary
- Preliminary Q3 EPS $1.28-$1.33 vs $1.44 prior year; net sales $265-$270M vs $299M.
- FY2021 guidance lowered: net sales $1.18-$1.20B (prev $1.24-$1.28B); EPS $5.80-$6.00 (prev $6.15-$6.50).
- CEO cites COVID disruptions, lockdowns, postponed events, and delayed product launches as headwinds.
- Board increases share repurchase authorization to $150M (includes $14M remaining).

## SEC filing metadata
- accession: 0001157523-21-001149
- form_type: 8-K
- ticker: USNA
- cik: 0000896264
- company_name: USANA HEALTH SCIENCES INC
- filed_at: 2021-09-16T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/896264/000115752321001149/0001157523-21-001149-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/896264/000115752321001149/a52493306.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-21-001149
- JSON: https://secwatch.observer/filing/0001157523-21-001149.json
- Plain text: https://secwatch.observer/filing/0001157523-21-001149.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.